8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Jan 21, 2026·SEC
Galectin Therapeutics Inc.(GALT)Earnings, Financials & Key Ratios
GALT•NASDAQ
$2.11
$136M mkt cap·Price updated May 7, 2026
AboutGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Show more
- Revenue$0
- EBITDA-$42M-11.5%
- Net Income-$47M-14.6%
- EPS (Diluted)-0.76-2.7%
- Interest Coverage-7.66+43.8%
GALT Key Insights
Galectin Therapeutics Inc. (GALT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GALT Price & Volume
Galectin Therapeutics Inc. (GALT) stock price & volume — 10-year historical chart
Loading chart...
GALT Growth Metrics
Galectin Therapeutics Inc. (GALT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM17.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM19.18%
Return on Capital
10 Years-172.33%
5 Years-181.48%
3 Years-276.45%
Last Year-
GALT Recent Earnings
Galectin Therapeutics Inc. (GALT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
Mar 31, 2026EPS
$0.08
Est $0.10
+20.0%
Revenue
—
Est $36M
Q2 2026
Mar 30, 2026EPS
$0.08
Est $0.10
+20.0%
Revenue
—
Est $36M
Q4 2025
Nov 14, 2025EPS
$0.13
Est $0.11
-18.2%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.12
Est $0.16
+25.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 31, 2026 | $0.08vs $0.10+20.0% | —vs $36M |
| Q2 2026 | Mar 30, 2026 | $0.08vs $0.10+20.0% | —vs $36M |
| Q4 2025 | Nov 14, 2025 | $0.13vs $0.11-18.2% | — |
| Q3 2025 | Aug 14, 2025 | $0.12vs $0.16+25.0% | — |
Based on last 12 quarters of dataView full earnings history →
GALT Peer Comparison
Galectin Therapeutics Inc. (GALT) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 AKBA | 316.54M | 1.18 | -56.73 | 47.46% | -8.83% | -62.72% | 6.63 | |
 MDGL | 12.27B | 534.86 | -41.62 | 432.05% | -27.32% | -50.15% | 0.59 | |
 ELVN | 2.39B | 40.29 | -22.02 | -24.22% | ||||
 CRNX | 4.55B | 43.48 | -8.78 | 6.41% | -31.43% | -43.96% | 0.05 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 HIMS | 6.63B | 25.67 | 50.32 | 59% | 5.47% | 23.73% | 2.07 | |
 ALDX | 104.08M | 1.73 | -1.84 | -87.71% | 0.22 |
Compare GALT vs Peers
Galectin Therapeutics Inc. (GALT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GALT Income Statement
Galectin Therapeutics Inc. (GALT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 7K | 1K | 0 | 35K | 36K | 41K | 32K | 33K | 37K | 22K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -7K▲ 0% | -1K▲ 85.7% | 0▲ 100.0% | -35K▲ 0% | -36K▼ 2.9% | -41K▼ 13.9% | -32K▲ 22.0% | -33K▼ 3.1% | -37K▼ 12.1% | -22K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 0% | 85.71% | 100% | - | -2.86% | -13.89% | 21.95% | -3.13% | -12.12% | - |
| Operating Expenses | 21.48M | 16.25M | 13.6M | 13.4M | 23.41M | 30.14M | 38.32M | 38.04M | 42.4M | 29.13M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 6.16M | 4.53M | 7.13M | 5.94M | 5.43M | 6.32M | 6.58M | 5.94M | 5.83M | 5.66M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 15.32M | 11.72M | 6.47M | 7.47M | 17.98M | 23.82M | 31.74M | 32.13M | 36.57M | 23.47M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -21.48M▲ 0% | -16.25M▲ 24.4% | -13.6M▲ 16.3% | -13.44M▲ 1.2% | -23.44M▼ 74.5% | -30.18M▼ 28.7% | -38.35M▼ 27.1% | -38.07M▲ 0.7% | -42.43M▼ 11.5% | -29.15M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -6.98% | 24.37% | 16.28% | 1.21% | -74.46% | -28.73% | -27.08% | 0.73% | -11.45% | - |
| EBITDA | -21.47M | -16.25M | -13.6M | -13.4M | -23.41M | -30.14M | -38.32M | -38.04M | -42.4M | -31.29M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -6.98% | 24.35% | 16.28% | 1.46% | -74.65% | -28.75% | -27.15% | 0.73% | -11.45% | 20.84% |
| D&A (Non-Cash Add-back) | 7K | 1K | 1K | 35K | 36K | 41K | 32K | 33K | 37K | 22K |
| EBIT | -21.48M | -16.23M | -13.56M | -13.21M | -23.38M | -30.04M | -37.74M | -38.27M | -41.51M | -30.19M |
| Net Interest Income | 0 | 12K | -298K | 144K | -21K | -486K | -981K | -2.56M | -5.2M | -6.93M |
| Interest Income | 45K | 24K | 38K | 231K | 66K | 3K | 52K | 230K | 338K | 184K |
| Interest Expense | 0 | 12K | 336K | 87K | 87K | 489K | 1.03M | 2.79M | 5.54M | 7.12M |
| Other Income/Expense | 45K | 12K | -298K | 144K | -21K | -348K | -424K | -2.99M | -4.61M | -8.15M |
| Pretax Income | -21.44M▲ 0% | -16.23M▲ 24.3% | -13.9M▲ 14.4% | -13.29M▲ 4.4% | -23.46M▼ 76.5% | -30.53M▼ 30.1% | -38.78M▼ 27.0% | -41.07M▼ 5.9% | -47.05M▼ 14.6% | -37.3M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -21.44M▲ 0% | -16.23M▲ 24.3% | -13.9M▲ 14.4% | -13.29M▲ 4.4% | -23.46M▼ 76.5% | -30.53M▼ 30.1% | -38.78M▼ 27.0% | -41.07M▼ 5.9% | -47.05M▼ 14.6% | -37.3M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -7.04% | 24.26% | 14.38% | 4.36% | -76.51% | -30.1% | -27.02% | -5.91% | -14.56% | 17.25% |
| Net Income (Continuing) | -21.44M | -16.23M | -13.9M | -13.29M | -23.46M | -30.53M | -38.78M | -41.07M | -47.05M | -37.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.73▲ 0% | -0.46▲ 37.0% | -0.35▲ 23.9% | -0.39▼ 11.4% | -0.41▼ 5.1% | -0.52▼ 26.8% | -0.65▼ 25.0% | -0.74▼ 13.8% | -0.76▼ 2.7% | -0.58▲ 0% |
| EPS Growth % | 12.05% | 36.99% | 23.91% | -11.43% | -5.13% | -26.83% | -25% | -13.85% | -2.7% | 19.18% |
| EPS (Basic) | -0.73 | -0.46 | -0.35 | -0.39 | -0.41 | -0.52 | -0.65 | -0.74 | -0.76 | - |
| Diluted Shares Outstanding | 29.22M | 35.52M | 39.41M | 52.24M | 57.03M | 58.53M | 59.39M | 60.16M | 62.31M | 64.2M |
| Basic Shares Outstanding | 29.22M | 35.52M | 39.41M | 52.24M | 57.03M | 58.53M | 59.39M | 60.16M | 62.31M | 64.2M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GALT Balance Sheet
Galectin Therapeutics Inc. (GALT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.79M | 3.82M | 8.83M | 48.21M | 29.46M | 41.82M | 20.55M | 27.71M | 17.25M | 12.73M |
| Cash & Short-Term Investments | 15.36M | 3.05M | 8.25M | 47.48M | 27.14M | 39.65M | 18.59M | 25.66M | 15.12M | 11.53M |
| Cash Only | 15.36M | 3.05M | 8.25M | 47.48M | 27.14M | 39.65M | 18.59M | 25.66M | 15.12M | 11.53M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 6K | 6K | 579K | 729K | 2.32M | 2.17M | 1.96M | 2.05M | 2.13M | 1.2M |
| Total Non-Current Assets | 1K | 342K | 174K | 258K | 135K | 7K | 733K | 490K | 243K | 136K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53K | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 342K | 174K | 258K | 135K | 7K | 733K | 437K | 243K | 797K |
| Total Assets | 15.79M▲ 0% | 4.16M▼ 73.7% | 9.01M▲ 116.4% | 48.47M▲ 438.2% | 29.6M▼ 38.9% | 41.83M▲ 41.3% | 21.29M▼ 49.1% | 28.2M▲ 32.5% | 17.5M▼ 38.0% | 12.87M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -40.19% | -73.66% | 116.44% | 438.16% | -38.93% | 41.31% | -49.11% | 32.49% | -37.96% | -200.34% |
| Total Current Liabilities | 3.78M | 2.97M | 2.11M | 2.82M | 5.4M | 9.03M | 13.01M | 15.68M | 35.41M | 136.44M |
| Accounts Payable | 910K | 608K | 297K | 1.66M | 1.29M | 1.8M | 3.89M | 6.43M | 5.66M | 5.39M |
| Days Payables Outstanding | 47.45K | 221.92K | - | 17.32K | 13.1K | 16.07K | 44.37K | 71.13K | 55.8K | 97.24K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21.12M | 122.28M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.19M | 1.57M | 517K | 147K | 3.27M | 6.49M | 8.11M | 8.07M | 1.89M | 4.84M |
| Current Ratio | 4.18x | 1.29x | 4.19x | 17.10x | 5.46x | 4.63x | 1.58x | 1.77x | 0.49x | 0.49x |
| Quick Ratio | 4.18x | 1.29x | 4.19x | 17.10x | 5.46x | 4.63x | 1.58x | 1.77x | 0.49x | 0.49x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 52K | 8K | 30.18M | 40.47M | 72.77M | 85.16M | 1.72M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 29.05M | 39.83M | 71.74M | 85.11M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 52K | 8K | 1.13M | 639K | 1M | 47K | 3.44M |
| Total Liabilities | 3.78M | 2.97M | 2.11M | 2.87M | 5.41M | 39.21M | 53.48M | 88.44M | 120.56M | 138.17M |
| Total Debt | 0 | 0 | 0 | 39K | 44K | 29.06M | 39.87M | 71.81M | 106.25M | 122.31M |
| Net Debt | -15.36M | -3.05M | -8.25M | -47.44M | -27.1M | -10.59M | 21.28M | 46.15M | 91.13M | 110.79M |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 11.11x | - | - | - | -0.98x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -3.91x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -3.54x |
| Interest Coverage | - | -1353.92x | -40.48x | -154.46x | -269.47x | -61.72x | -37.13x | -13.64x | -7.66x | -4.24x |
| Total Equity | 12.02M▲ 0% | 1.19M▼ 90.1% | 6.9M▲ 478.2% | 45.59M▲ 561.0% | 24.19M▼ 46.9% | 2.62M▼ 89.2% | -32.19M▼ 1330.7% | -60.24M▼ 87.1% | -103.07M▼ 71.1% | -125.3M▲ 0% |
| Equity Growth % | -52.03% | -90.07% | 478.21% | 560.99% | -46.94% | -89.19% | -1330.66% | -87.12% | -71.1% | -207.14% |
| Book Value per Share | 0.41 | 0.03 | 0.18 | 0.87 | 0.42 | 0.04 | -0.54 | -1.00 | -1.65 | -1.95 |
| Total Shareholders' Equity | 12.02M | 1.19M | 6.9M | 45.59M | 24.19M | 2.62M | -32.19M | -60.24M | -103.07M | -125.3M |
| Common Stock | 33K | 36K | 41K | 56K | 56K | 59K | 59K | 61K | 62K | 64K |
| Retained Earnings | -163.7M | -181.17M | -196.22M | -216.39M | -240M | -270.69M | -309.57M | -354.37M | -401.57M | -426.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GALT Cash Flow Statement
Galectin Therapeutics Inc. (GALT) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.41M | -15.89M | -10.18M | -10.85M | -20.6M | -24.31M | -31.06M | -32.97M | -41.77M | -41.77M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 3.38% | 3.15% | 35.95% | -6.57% | -89.91% | -17.99% | -27.76% | -6.15% | -26.7% | -56.26% |
| Net Income | -21.44M | -16.23M | -13.9M | -13.29M | -23.46M | -30.53M | -38.78M | -41.07M | -47.05M | -37.3M |
| Depreciation & Amortization | 7K | 1K | 0 | 35K | 36K | 41K | 32K | 33K | 37K | 22K |
| Stock-Based Compensation | 2.48M | 1.1M | 4.45M | 1.68M | 1.8M | 2.08M | 2.87M | 2.26M | 2.45M | 1.46M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 45K | 348K | 87K | 87K | 351K | -147K | 1.13M | 512K | 3.08M |
| Working Capital Changes | 2.54M | -804K | -1.07M | 641K | 942K | 3.75M | 4.97M | 4.68M | 2.28M | 2.12M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.42M | -812K | -1.09M | 997K | 2.54M | 3.69M | 4.24M | 2.67M | -2.07M | -4.11M |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 5.92M | 3.58M | 15.38M | 50.08M | 263K | 36.81M | 10M | 40.03M | 31.23M | 15.09M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 30M | 10M | 30M | 30M | 11M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 263K | 1000K | 0 | 0 | 1000K | 2.7M |
| Dividends Paid | -741K | -1.23M | -915K | -394K | -137K | -171K | 0 | 0 | -91K | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 741K | 1.23M | 915K | 0 | 137K | 171K | 0 | 10.03M | 91K | 443K |
| Net Change in Cash | -10.48M▲ 0% | -12.31M▼ 17.4% | 5.2M▲ 142.2% | 39.23M▲ 654.4% | -20.34M▼ 151.8% | 12.51M▲ 161.5% | -21.06M▼ 268.4% | 7.07M▲ 133.6% | -10.54M▼ 249.1% | -15.54M▲ 0% |
| Free Cash Flow | -16.41M▲ 0% | -15.89M▲ 3.2% | -10.18M▲ 35.9% | -10.85M▼ 6.6% | -20.6M▼ 89.9% | -24.31M▼ 18.0% | -31.06M▼ 27.8% | -32.97M▼ 6.1% | -41.77M▼ 26.7% | -30.62M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 3.38% | 3.15% | 35.95% | -6.57% | -89.91% | -17.99% | -27.76% | -6.15% | -26.7% | 9.07% |
| FCF per Share | -0.56 | -0.45 | -0.26 | -0.21 | -0.36 | -0.42 | -0.52 | -0.55 | -0.67 | -0.67 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.98x | 0.73x | 0.82x | 0.88x | 0.80x | 0.80x | 0.80x | 0.89x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GALT Key Ratios
Galectin Therapeutics Inc. (GALT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -115.67% | -245.84% | -343.59% | -50.65% | -67.25% | -227.74% | - | - | - | 32.59% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 179.95% |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 11.11x | - | - | - | -0.98x |
| Interest Coverage | - | -1353.92x | -40.48x | -154.46x | -269.47x | -61.72x | -37.13x | -13.64x | -7.66x | -4.24x |
| FCF Conversion | 0.77x | 0.98x | 0.73x | 0.82x | 0.88x | 0.80x | 0.80x | 0.80x | 0.89x | 0.82x |
GALT SEC Filings & Documents
Galectin Therapeutics Inc. (GALT) SEC filings — annual & quarterly reports (10-K, 10-Q)
GALT Frequently Asked Questions
Galectin Therapeutics Inc. (GALT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Galectin Therapeutics Inc. (GALT) grew revenue by 0.0% over the past year. Growth has been modest.
Galectin Therapeutics Inc. (GALT) reported a net loss of $37.3M for fiscal year 2024.
Dividend & Returns
Galectin Therapeutics Inc. (GALT) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
Galectin Therapeutics Inc. (GALT) had negative free cash flow of $30.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More GALT
Galectin Therapeutics Inc. (GALT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates